Adimab LLC is not the typical biotech. It's a venture-backed, yet profitable company that has made its name as a partner of choice for antibody drug discovery. In fact, Adimab recently inked a deal for its 50th program, which is particularly impressive given that the firm only began partnering activities about five years ago.